The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended granting a marketing authorization for ketoconazole (Ketoconazole HRA; Laboratoire HRA ...

Here is some hope for people of the European Union suffering from Cushing’s syndrome who cannot undergo surgery. The European Medicines Agency has recommended the approval for the use of a drug ...

Please provide your email address to receive an email when new articles are posted on . Ketoconazole led to normal urinary free cortisol levels for 63% of adults with Cushing’s disease. Remission was ...

Multicyclic, dose-intensive chemotherapy supported by sequential reinfusion of hematopoietic progenitors in whole blood. A retrospective chart review was undertaken for 15 consecutive patients with ...

In patients with Cushing’s syndrome maintained on Recorlev, a lower baseline mUFC was associated with higher cortisol normalization rate. Lower mUFC at baseline was also associated with lower ...

Expert Rev Endocrinol Metab. 2013;8(2):183-193. Mitotane reduces cortisol synthesis through the inhibition of 11B-hydroxylase, 18-hydroxylase, 3-α hydroxylase, hydroxysteroid dehydrogenase and several ...

Cushing's disease, which is caused by an adrenocorticotropin-secreting pituitary adenoma, is associated with increased morbidity and mortality. 1 Currently, there is no effective medical therapy for ...

Please provide your email address to receive an email when new articles are posted on . “The findings show that levoketoconazole [Recorlev, Strongbridge Biopharma] was safe and effective in a ...

This drug has boxed warnings. A boxed warning is the most serious warning from the Food and Drug Administration (FDA). It alerts doctors and patients about drug effects that may be dangerous.